Sign up


Match Document Document Title
8632776 Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for Parkinson's disease, dementia with lewy bodies and other α-synucleinopathies  
Antibodies and fragments thereof have high affinity for human α-synuclein protofibrils and low binding of α-synuclein monomers, wherein the antibodies or fragments have specified Complementarity D...
8633301 Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine  
Pharmaceutical composition comprising an antibody specifically recognizing CD38 and vincristine.
8628772 Surface protein (HBsAg) variant of the hepatitis B virus  
The invention relates to sequences of a novel variant of the Hepatitis B surface antigen (HBsAg) and to methods for detecting, in patient samples, nucleic acids, antigens, and antibodies directed...
8628778 Humanized monoclonal antibodies to hepatocyte growth factor  
The present invention is directed toward a humanized neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising...
8628771 CA IX-specific inhibitors  
Therapeutic methods for inhibiting the growth of preneoplastic/neoplastic vertebrate cells that abnormally express MN protein are disclosed. Screening assays are provided for identifying compounds,...
8628774 Compositions and methods for treating and diagnosing cancer  
The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in...
8629250 Hepcidin, hepcidin antagonists and methods of use  
The invention relates to purified, correctly folded hepcidin, antibodies that bind hepcidin, and methods of making and using such materials. Also provide are methods of treated hepcidin-related...
8628773 Antigen binding proteins  
Antigen binding proteins, such as antibodies, that interact with Epidermal Growth Factor Receptor (EGFR) are described. Methods of treating cancers and other diseases by administering a...
8623354 Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment  
The present invention relates generally to treatment and prophylactic protocols for cellular diseases or disorders, such as diseases and disorders associated with abnormal cellular proliferation....
8623355 Methods for suppressing acute rejection of a heart transplant  
The effect of anti-IL-6 receptor antibodies in suppressing cytotoxic T cell induction was examined. The results showed that CTL activity against alloantigens was statistically significantly reduced...
8623366 Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide  
The invention features methods for preventing or treating visceral pain, including pain associated with functional bowel disorder, inflammatory bowel disease and interstitial cystitis, by...
8623353 TLR2 antagonistic antibody and use thereof  
The present invention is directed to a cross-reactive antibody that specifically inhibits or blocks mammalian Toll-like receptor 2 (TLR2)-mediated immune cell activation. The invention is further...
8623357 Therapeutic antibodies  
A pharmaceutical comprising a therapeutic protein that hinds to a therapeutic target, the protein being modified with a compound that inhibits binding of the protein to the therapeutic target, the...
8623349 Systems, methods and microrganisms for antibody production with type III secretion system  
Exemplary embodiments disclosed herein include a microorganism that produces, secretes and injects recombinant antibodies into eukaryote cells said the described microorganisms can be used to...
8623356 Demibodies: dimerization-activated therapeutic agents  
The present invention relates generally to a set of synthetic immunointeractive molecules referred to herein as “demibodies” which are useful in targeting particular cells in a subject. More par...
8623416 Formulations comprising aminosterols  
This invention relates to stable aminosterol phosphate compositions. The aminosterol phosphate compositions permit administration without associated tissue damage and achieve a sustained release...
8623369 Anti-ICAM-1 single domain antibody and uses thereof  
Anti-ICAM-1 VHH single-domain antibodies (sdAbs) are generated by immunizing a llama with recombinant ICAM-1. These antibodies are linked to an imaging moiety for in vivo or ex vivo imaging of...
8623370 Vaccinia virus H3L and B5R specific monoclonal antibodies and methods of making and using same  
The invention relates to antibodies and subsequences thereof that specifically bind to poxvirus B5R envelope protein, antibodies and subsequences thereof that specifically bind to pox virus H3L...
8623368 Human recombinant monoclonal antibody that specifically binds to VCAM-1 and inhibits adhesion and transmigration between leukocytes and endothelial cells  
The present invention relates to a human recombinant monoclonal antibody that specifically binds to human Vascular Cell Adhesion Molecule-1 (VCAM-1) to inhibit adhesion between leukocytes and...
8623372 Antibodies for preventing and treating attaching and effacing Escherichia coli (AEEC) associated diseases  
The present invention relates to antibodies immunologically specific for an attaching and effacing Escherichia coli (AEEC) virulence-associated protein, products, compositions and methods and to...
8617550 Treatment of vasculitis with IL-6 antagonist  
To provide a preventive and/or therapeutic agent for vasculitis such as polyarteritis nodosa, the aortitis syndrome, and a vasculitis that is associated with immunological abnormalities, said agent...
8617556 Gram-positive bacteria specific binding compounds  
The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic...
8617545 Methods for use with BAFF antagonists  
BAFF plays a central role in acquired immunity. The disclosure identifies BAFF-responsive genes that are substantially upregulated by administration of BAFF and substantially downregulated by...
8618053 FGF21 mutants multimers and uses thereof  
The invention provides a multimer comprising at least a first and a second chain, the first chain comprising the polypeptide of SEQ ID NO:4, wherein the leucine at position 98 is substituted with...
RE44681 Compositions and methods for inhibiting growth of SMAD4-deficient cancers  
The present invention is in the fields of cell biology, immunology and oncology. The invention relates to the discovery that there is a relationship between the expression levels of the tumor...
8617553 Use of goat serum for veterinary treatment  
Methods for veterinary treatment of mammals are described, for treatment of conditions having an inflammatory component. The methods are particularly suited to treatment of cats, dogs, or horses.
8617613 Polymer-based sustained release device  
This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically...
8618252 Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto  
The compositions and methods of the present invention are based, in part, on our discovery that an effector function mediated by an Fc-containing polypeptide can be altered by modifying one or more...
8617554 Anti-human CD52 immunoglobulins  
The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates...
8617546 Anticancer agent comprising anti-PD-1 antibody or anti-PD-L1 antibody  
Provided is an anticancer agent which comprises an anti-PD-1 antibody or an anti-PD-L1 antibody as an active ingredient, functioning to reverse the unresponsiveness of iNKT cells in which anergy...
8614301 Methods of treating cancer using anti CD24 antibodies  
Anti-CD24 antibodies and adjuvant combinations thereof with chemotherapeutic agents or toxins, which can be used to inhibit growth of CD24-expressing cancer cells and prevent and treat cancer are...
8614295 Antibody molecules having specificity for human OX40  
The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
8613907 Compositions that inhibit proliferation of cancer cells  
Disclosed are compositions and methods for reducing the proliferation of cancer cells through targeted interactions with integrins.
8613919 High concentration antibody and protein formulations  
Provided are high concentration, salt-free antibody and other protein formulations that are substantially isosmotic and of low viscosity. Also provided are methods for the treatment of diseases...
8613926 Anti-C5a receptor antibodies  
The present invention concerns human antibodies recognizing the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based...
8609089 Compositions of PD-1 antagonists and methods of use  
Methods of treating cancer and infectious diseases utilizing a treatment regimen comprising administering a compound that reduces inhibitory signal transduction in T cells, in combination with a...
8609817 Anti-hepcidin-25 selective antibodies and uses thereof  
Monoclonal antibodies are provided that bind to the N-terminus of human hepcidin-25 and are characterized as having high affinity and selectivity for the polypeptide. The antibodies of the...
8609101 Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies  
The invention provides a GM-CSF neutralizing human monoclonal antibody, 1783J22, as well as methods of making and use thereof. The monoclonal antibody is further characterized by its ability to...
8609111 Antibodies against clostridium difficile toxins and uses thereof  
Antibodies that specifically bind to toxins of C. difficile, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein.
8603474 Membrane transporter NaPi2b (SCL34A1) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy  
The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide...
8603465 Methods for treatment of polyposis  
The present invention relates to method for treating medical disorders mediated by mutations in the APC gene by administering an IGF1R inhibitor. Such disorders include, for example, familial...
8603480 Human cytomegalovirus neutralizing antibodies and use thereof  
The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a...
8603469 Methods of treating cancer with human monoclonal antibodies against interleukin 8  
Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal,...
8603468 Neutralization of HCV  
Aspects of the present invention concern compositions that induce and/or improve an immune response to hepatitis C virus (HCV). Methods of making and using compositions that include epitopes of the...
8603470 Use of IL-20 antagonists for treating liver diseases  
Reducing liver fibrosis in a subject having or being suspected of having a liver disease using an IL-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by IL-20. Such...
8603467 Monoclonal antibodies binding to avian influenza virus subtype H5 haemagglutinin and uses thereof  
The present invention provides monoclonal antibodies that bind specifically to H5 subtype avian influenza virus hemagglutinin (HA) proteins, and can block the binding activity of at least 50% of...
8603466 Agonist antibodies against TSHR  
The invention provides antibodies that bind the thyroid stimulating hormone receptor (TSHR), especially in humans, and their uses in diagnostic and therapeutic roles. The invention also provides...
8603485 Bystander immune suppression as a predictor for response to a vaccine  
The present invention relates to antigen-specific immune regulatory response. Methods for detecting an antigen-specific immune regulatory response, methods for selecting candidate vaccine...
8603481 Therapeutic agents for solid tumors  
A therapeutic agent for solid tumors, the agent comprising as an active ingredient, an antibody that specifically binds to a protein having the amino acid sequence represented by SEQ ID NO:2 or an...
8604169 Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer  
A novel gene 251P5G2 and its encoded protein, and variants thereof, are described wherein 251P5G2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the...